Pharmaceutical firm
The
The newest version of the company's vaccine targets the XBB.1.5 subvariant of the virus, which is currently one of the most prominent strains in
The update is in line with FDA recommendations.
"The agility of our mRNA platform has enabled us to update Spikevax,
"In addition, our preliminary clinical testing has demonstrated that mRNA-1273.815 is effective in generating an immune response against the current XBB variants of concern. Over the past three years, Spikevax has consistently reduced hospitalizations and severe disease outcomes from COVID-19, and we encourage individuals to speak to their healthcare providers about receiving an updated vaccine."
The company last week said preclinical trial data from studies on mice pointed to the new vaccine producing a stronger response against XBB variants of the virus than previous versions.
Copyright 2023 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source